Jovana Milic

Jovana Milic

Auto-generated profile, based on publicly available information

Jovana Milic

Department of Surgical, Medical, Dental and Morphological Sciences University of Modena and Reggio Emilia Modena Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
EFErica Franceschini
Erica Franceschini
ACAlessandro Cozzi-Lepri
Alessandro Cozzi-Lepri
ASAntonella Santoro
Antonella Santoro
EBErica Bacca
Erica Bacca
GLGuido Lancellotti
Guido Lancellotti
CMCristina Mussini
Cristina Mussini
Background: Herpes simplex 1 co-infections in patients with COVID-19 are considered relatively uncommon; some reports on re-activations in patients in intensive-care units were published. The aim of the study was to analyze herpetic re-activations and their clinical manifestations in hospitalized COVID-19 patients, performing HSV-1 PCR on plasma twice a week. Methods: we conducted a prospective, observational, single-center study involving 70 consecutive patients with severe/critical SARS-CoV-2 pneumonia tested for HSV-1 hospitalized at Azienda Ospedaliero-Universitaria of Modena. Results: of these 70 patients, 21 (30.0%) showed detectable viremia and 13 (62%) had clinically relevant manifestations of HSV-1 infection corresponding to 15 events (4 pneumonia, 5 herpes labialis, 3 gingivostomatitis, one encephalitis and two hepatitis). HSV-1 positive patients were more frequently treated with steroids than HSV-1 negative patients (76.2% vs. 49.0%, p = 0.036) and more often underwent mechanical ventilation (IMV) (57.1% vs. 22.4%, p = 0.005). In the unadjusted logistic regression analysis, steroid treatment, IMV, and higher LDH were significantly associated with an increased risk of HSV1 re-activation (odds ratio 3.33, 4.61, and 16.9, respectively). The association with the use of steroids was even stronger after controlling for previous use of both tocilizumab and IMV (OR = 5.13, 95% CI:1.36–19.32, p = 0.016). The effect size was larger when restricting to participants who were treated with high doses of steroids while there was no evidence to support an association with the use of tocilizumab Conclusions: our study shows a high incidence of HSV-1 re-activation both virologically and clinically in patients with SARS-CoV-2 severe pneumonia, especially in those treated with steroids.

21 June 2022 in AIDS
Verified
Journal Article
Closed access
JMJovana Milic
Jovana Milic
SRStefano Renzetti
Stefano Renzetti
DFDavide Ferrari
Davide Ferrari
SBSara Barbieri
Sara Barbieri
MMMarianna Menozzi
Marianna Menozzi
GGGiovanni Guaraldi
Giovanni Guaraldi
Objective: The primary objective was to explore weight and BMI changes in people with HIV (PWH) undergoing integrase strand transfer inhibitors (INSTI)-based regimens (vs. non-INSTI) in a large cohort and in the subsets of individuals without diabetes and insulin resistance (IR) at the time of switch to INSTI. The secondary objective was to identify risk factors for IR and cut-off of weight or BMI increase associated with IR in PWH switching to INSTI. Design: A longitudinal matched-cohort study including PWH attending Modena HIV Metabolic Clinic, Italy. Methods: PWH were divided into two groups: non-INSTI and INSTI-switch. The effect of switching to INSTI on weight and BMI change was tested through a linear mixed model. A mediation analysis explored the mediation effect of weight and BMI change in the association between the switch to INSTI and IR. Results: We analyzed 2437 PWH (1025 INSTI-switch, 1412 non-INSTI), in 54 826 weight assessments. Trends for weight increase were significantly higher in early-INSTI-switch (vs. early-non-INSTI), but no difference was observed in the late period after the switch. In the subset of 634 PWH without IR, switching to INSTI (vs. non-INSTI) was associated with a lower risk of IR (hazard ratio = 0.70, 95% confidence interval: 0.51, 0.98). A weight increase by 1% reduced the total protective effect of INSTI by 21.1% over 1 year of follow-up, which identifies a 5% weight increase as a clinically meaningful weight gain definition. Conclusion: A cut-off of 5% weight gain from the time of INSTI-switch is associated with IR, which may be a clinically meaningful endpoint that could be used in clinical and research settings.

30 June 2021 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
Gaetano AlfanoGaetano Alfano
Gaetano Alfano
AFAnnachiara Ferrari
Annachiara Ferrari
FFFrancesco Fontana
Francesco Fontana
GMGiacomo Mori
Giacomo Mori
GLGiulia Ligabue
Giulia Ligabue
GGGiovanni Guaraldi
Giovanni Guaraldi
The prognostic value of within-day sCr variation serum creatinine variation is unknown in the setting of the novel coronavirus disease 2019 (COVID-19). We evaluated the prognostic significance of 24-hour serum creatinine variation in COVID-19 patients. A monocentric retrospective analysis was conducted in COVID-19 patients not admitted to the intensive care unit. Three groups were subdivided based on 24 hours serum creatinine variation from admission. In the stable kidney function group, 24-hour serum creatinine variation ranged from +0.05 to -0.05 mg/dL; in the decreased kidney function group, 24-hour serum creatinine variation was >0.05 mg/dL; in the improved kidney function group, 24-hour serum creatinine variation was <-0.05 mg/dL. The study population included 224 patients with a median age of 66.5 years and a predominance of males (72.3%). Within 24 hours of admission, renal function remained stable in 37.1% of the subjects, whereas it displayed improved and deteriorated patterns in 45.5% and 17.4%, respectively. Patients with decreased kidney function were older and had more severe COVID-19 symptoms than patients with stable or improved kidney function. About half of patients with decreased kidney function developed an episode of acute kidney injury (AKI) during hospitalization. Decreased kidney function was significantly associated with AKI during hospitalization (hazard ratio [HR], 4.6; 95% confidence interval [CI], 1.9-10.8; p < 0.001) and was an independent risk factor for 30-day in-hospital mortality (HR, 5.5; 95% CI, 1.1-28; p = 0.037). COVID-19 patients with decreased kidney function within 24 hours of admission were at high risk of AKI and 30-day in-hospital mortality.

7 August 2020 in AIDS
Verified
Journal Article
Closed access
JMJovana Milic
Jovana Milic
VMValentina Menozzi
Valentina Menozzi
FSFilippo Schepis
Filippo Schepis
AMAndrea Malagoli
Andrea Malagoli
GBGiulia Besutti
Giulia Besutti
GGGiovanni Guaraldi
Giovanni Guaraldi
Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH).Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018–2019.Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP ≥248 dB/m), while significant liver fibrosis or cirrhosis (stage ≥F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates.Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4+cell count 700 cells/μl, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6–15], vitamin D insufficiency (OR = 1.94, 1.2–3.2), obesity (OR = 8.1, 4.4–14.6), diabetes (OR = 3.2, 1.9–5.6), metabolic syndrome (OR = 2.41, 1.47–3.95) and osteoporosis (OR = 0.37, 0.16–0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3–3.5), fibrosis (OR = 2, 1–3.7), NAFLD with fibrosis (OR = 9.2, 5.2–16.8), diabetes (OR = 1.7, 1–2.7) and multimorbidity (OR = 2.5, 1.5–4).Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH.

16 October 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
ACAndrea Cossarizza
Andrea Cossarizza
ACAlessandro Cozzi-Lepri
Alessandro Cozzi-Lepri
MMMarco Mattioli
Marco Mattioli
APAnnamaria Paolini
Annamaria Paolini
ANAnita Neroni
Anita Neroni
CMCristina Mussini
Cristina Mussini
Background: The aim of this randomized clinical trial (RCT) was to compare immunological changes in virally suppressed people living with HIV (PLWH) switching from a three-drug regimen (3DR) to a two-drug regimen (2DR).Methods: An open-label, prospective RCT enrolling PLWH receiving a 3DR who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir/lamivudine (DTG/3TC) was performed. Blood was taken at baseline and months 6 and 12. The primary outcome was the change in CD4+ or CD8+ T-cell counts and CD4/CD8 ratio over time points. The secondary outcomes were the changes in immunological and inflammatory parameters. Parametric mixed-linear models with random intercepts and slopes were fitted separately for each marker after controlling for potential confounders.Results: Between the two arms (33 PLWH each), there was no difference in CD4+ or CD8+ T cells, CD4/CD8 ratio, and IL-6 trajectories. PLWH switching to DTG/3TC had increased levels of both transitional memory and terminally differentiated CD4+ T cells (arm–time interaction p-value = 0.02) and to a lesser extent for the corresponding CD8+ T-cell subsets (p = 0.09). Significantly lower levels of non-classical monocytes were detected in the B/F/TAF arm at T6 (diff = −6.7 cells/mm3; 95% CI; −16, +2.6; p-value for interaction between arm and time = 0.03). All differences were attenuated at T12.Conclusion: No evidence for a difference in absolute CD4+ and CD8+ T-cell counts, CD4/CD8 ratio, and IL-6 trajectories by study arm over 12 months was found. PLWH on DTG/3TC showed higher levels of terminally differentiated and exhausted CD4+ and CD8+ T lymphocytes and non-classical monocytes at T6. Further studies are warranted to better understand the clinical impact of our results.Clinical Trial Registration: https://clinicaltrials.gov, identifier NCT04054089.

23 March 2022 in The Aging Male
Verified
Journal Article
Open access
SVSara De Vincentis
Sara De Vincentis
MDMaria Chiara Decaroli
Maria Chiara Decaroli
FFFlaminia Fanelli
Flaminia Fanelli
CDChiara Diazzi
Chiara Diazzi
MMMarco Mezzullo
Marco Mezzullo
VRVincenzo Rochira
Vincenzo Rochira
Data about classification of hypogonadism and estrogen deficiency in male people living with HIV (PLWH) are scanty.To investigate the prevalence and characterization of biochemical hypogonadism and...